ClinicalTrials.gg
CompletedNCT06326060Updated Apr 15, 2026

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

A Phase 2 interventional study of NNC0519-0130 and Placebo in Obesity, sponsored by Novo Nordisk A/S. Completed at 70 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Enrollment
47th of 166
354 · median 138
Started
2024
with 21 others
Phase 2
13 of 207
1 open now
Registered
122nd of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 47th largest by enrollment of the 166 interventional ones that give a count, is one of 22 that started in 2024, is one of 13 in phase 2, and was the 122nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of non-, or male.

    a. For US only: Female of childbearing potential using highly effective non-systemic methods of with low user-dependency at least 2 months prior to screening and willingness to continue using it through-out the study, or male.

  • Age 18-75 years (both inclusive) at the time of signing the .
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.
  • a) ≥ 27.0 kg/m2 with the presence of at least one weight-related co-morbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
  • b) BMI ≥ 30.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • greater than equal to 6.5% (48 millimoles per mole (mmol/mol)) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes mellitus.
  • Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Dosing scheme a: NNC0519-0130

    Participants will receive NNC0519-0130 at 1 dose level subcutaneously (s.c.) once-weekly up to 36 weeks.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme a: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.

    Drug: Placebo

  • Experimental
    Dosing scheme b: NNC0519-0130

    Participants will receive NNC0519-0130 at 2 dose levels s.c. once-weekly up to 36 weeks.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme b: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.

    Drug: Placebo

  • Experimental
    Dosing scheme c: NNC0519-0130

    Participants will receive NNC0519-0130 at 3 dose levels s.c. once-weekly up to 36 weeks.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme c: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.

    Drug: Placebo

  • Experimental
    Dosing scheme d: NNC0519-0130

    Participants will receive NNC0519-0130 at 4 dose levels s.c. once-weekly up to 36 weeks.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme d: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.

    Drug: Placebo

  • Experimental
    Dosing scheme e: NNC0519-0130

    Participants will receive NNC0519-0130 at 5 dose levels s.c. once-weekly up to 36 weeks.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme e: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.

    Drug: Placebo

  • Experimental
    Dosing scheme f: NNC0519-0130

    Participants will receive NNC0519-0130 at 6 dose levels s.c. once-weekly up to 36 weeks.

    Drug: NNC0519-0130

  • Placebo comparator
    Dosing scheme f: Placebo

    Participants will receive NNC0519-0130 matched placebo s.c. once-weekly up to 36 weeks.

    Drug: Placebo

  • Active comparator
    Dosing scheme g: Tirzepatide

    Participants will receive tirzepatide at 6 dose levels s.c. once weekly up to 36 weeks.

    Drug: Tirzepatide

Interventions

  • NNC0519-0130 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

  • Tirzepatide will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured in percentage of body weight.

    Time frame: From baseline (week 0) to end of treatment (week 36)

Secondary outcomes

  1. Change in body weight

    Measured in kilograms (kg)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  2. Achievement of greater than equal to (≥) 5% weight reduction

    Count of participants

    Time frame: From baseline (week 0) to end of treatment (week 36)

  3. Achievement of ≥ 10% weight reduction

    Count of participants

    Time frame: From baseline (week 0) to end of treatment (week 36)

  4. Achievement of ≥ 15% weight reduction

    Count of participants

    Time frame: From baseline (week 0) to end of treatment (week 36)

  5. Achievement of ≥ 20% weight reduction

    Count of participants

    Time frame: From baseline (week 0) to end of treatment (week 36)

  6. Change in body mass index (BMI)

    Measured in Kilogram per meter square (Kg/m\^2)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  7. Change in waist circumference

    Measured in centimeter (cm)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  8. Change in glycated hemoglobin (HbA1c)

    Measured in percentage point (%-point)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  9. Change in fasting plasma glucose (FPG)

    Measured in millimoles per liter (mmol/L)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  10. Change in systolic blood pressure (SBP)

    Measured in milliters of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 36)

  11. Change in high sensitivity C-Reactive protein (hsCRP)

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  12. Change in total cholesterol

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  13. Change in high-density lipoprotein (HDL) cholesterol

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  14. Change in low-density lipoprotein (LDL) cholesterol

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  15. Change in triglycerides

    Ratio to baseline

    Time frame: From baseline (week 0) to end of treatment (week 36)

  16. Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) Physical composite score

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  17. Change in IWQOL-Lite-CT Psychosocial composite score

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  18. Change in IWQOL-Lite-CT Physical Function score

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  19. Change in IWQOL-Lite-CT Total score

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Total score range is 0-100. Composite score ranges are: physical composite (0-100), psychosocial composite (0-100), and physical function composite (0-100).

    Time frame: From baseline (week 0) to end of treatment (week 36)

  20. Number of adverse events

    Count of events

    Time frame: From baseline (week 0) to end of treatment (week 40)

07

Study locations

70 sites
  • Centricity Research-Arizona
    Mesa, Arizona 85206, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Unity Health-Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • FDRC
    Costa Mesa, California 92627, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • UCLA Health Southbay Endocrine
    Torrance, California 90505, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Univ of Colorado at Denver
    Aurora, Colorado 80045, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • Jacksonville Ctr For Clin Res
    Jacksonville, Florida 32216, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Midwest Inst For Clin Res
    Indianapolis, Indiana 46260, United States
  • Velocity Clin. Res Valparaiso
    Valparaiso, Indiana 46383, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Centennial Medical Group
    Columbia, Maryland 21045, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • NYU Bariatric Surgical Ctr
    New York, New York 10016, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Velocity Clinical Res. Inc Vestal
    Vestal, New York 13850, United States
  • Medication Mgmnt, LLC_Grnsboro
    Greensboro, North Carolina 27405, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Physicians East Endocrinology
    Greenville, North Carolina 27834, United States
  • Piedmont Healthcare Statesville
    Statesville, North Carolina 28625, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Velocity Clinical Res
    Cleveland, Ohio 44122, United States
  • Remington Davis Inc
    Columbus, Ohio 43215, United States
  • Providence Health Partners Ctr
    Dayton, Ohio 45439, United States
  • Centricity Research - Ohio
    Dublin, Ohio 43016, United States
  • Family Practice Center of Wadsworth Inc.
    Wadsworth, Ohio 44281-9236, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73072, United States
  • The University of Penn Center
    Philadelphia, Pennsylvania 19104-3317, United States
  • Preferred Primary Care Physicians_Pittsburgh
    Pittsburgh, Pennsylvania 15243, United States
  • Velocity Clin Res Providence
    East Greenwich, Rhode Island 02818, United States
  • Medical University Of South Carolina
    Charleston, South Carolina 29425, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Holston Medical Group Pc
    Bristol, Tennessee 37620-7352, United States
  • Baylr Sctt White Rs Inst, Endo
    Dallas, Texas 75226, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • UT Southwestern Medical Center - Lingvay
    Dallas, Texas 75390, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Washington Cntr Weight Mgmt
    Arlington, Virginia 22206, United States
  • Health Res of Hampton Roads
    Newport News, Virginia 23606, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • National Clin Res Inc.
    Richmond, Virginia 23294, United States
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
  • Paratus Clinical
    Bruce, Australian Capital Territory 2617, Australia
  • Paratus Clinical
    Blacktown, New South Wales 2148, Australia
  • Northern Beaches Clinical Research
    Brookvale, New South Wales 2100, Australia
  • Momentum Clinical Research Darlinghurst
    Darlinghurst, New South Wales 2010, Australia
  • Paratus Clinical
    Kanwal, New South Wales 2259, Australia
  • Novatrials
    Kotara, New South Wales 2289, Australia
  • Sutherland Shire Clinical Research
    Miranda, New South Wales 2228, Australia
  • University of Sunshine Coast
    Birtinya, Queensland 4575, Australia
  • Paratus Clinical
    Herston, Queensland 4006, Australia
  • University of Sunshine Coast
    Morayfield, Queensland 4506, Australia
  • University of Sunshine Coast
    Sippy Downs, Queensland 4556, Australia
  • University of Sunshine Coast
    South Brisbane, Queensland 4101, Australia
  • Momentum Clinical Research
    Taringa, Queensland 4068, Australia
  • Momentum Clinical Research
    Tarragindi, Queensland 4121, Australia
  • CMAX Clinical Research
    Norwood, South Australia 5067, Australia
  • Emeritus Research Melbourne
    Camberwell, Victoria 3124, Australia
  • Austin Health, Metabolic Disorders Centre
    Heidelberg Heights, Victoria 3081, Australia
  • Momentum Clinical Research
    St Albans, Victoria 3021, Australia
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
  • OCROM Clinic_Internal medicine
    Suita-shi, Osaka 565-0853, Japan
  • ToCROM Clinic_Internal Medicine
    Tokyo, 160-0008, Japan
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Apr 2025, 12 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 12 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2024
First posted
Mar 22, 2024
StartActual
Mar 18, 2024
Primary completionActual
Apr 10, 2025
CompletionActual
May 1, 2025
Results delay requested
Apr 8, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326060
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Mar 18, 2024
Primary completion
Apr 10, 2025
Completion
May 1, 2025
Last update
Apr 15, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0519-0130

Start the discussion